References
- Bainbridge JL, Corboy JR. Multiple sclerosis. In: Dipiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. 7th edn. New York, NY: McGraw-Hill Companies, Inc, 2008
- Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
- McDowell TY, Amr S, Langenberg P, et al. Time of birth, residential solar radiation and age at onset of multiple sclerosis. Neuroepidemiology 2010;34:238-44
- Wallin MT, Culpepper WJ, Coffman P, et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 2012;135:1778-85
- World Health Organization. Atlas: Multiple Sclerosis Resources in the World, 2008. Geneva: World Health Organization, 2008. http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf. Accessed November 2, 2014
- Klevan G, Jacobsen CO, Aarseth JH, et al. Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurol Scand 2014;129:21-6
- Mackenzie IS, Morant SV, Bloomfield GA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 2014;85:76-84
- Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Mult Scler 2012;18:41-5
- Evans D, Sykes J. Disease modifying drugs - a guide to treatments for relapsing MS. Letchworth Garden City, Hertfordshire, UK: Multiple Sclerosis Trust, 2015. https://support.mstrust.org.uk/shop?prodid=90. Accessed January 30, 2016
- Scottish Medicines Consortium. SMC - Briefing Note - No. 86, January 2015. Scottish Medicines Consortium advice to NHS-Scotland. Glasgow: Scottish Medicines Consortium, 2015. https://www.scottishmedicines.org.uk/files/briefing-notes/2014/SMC_BN_January_2015.pdf. Accessed April 15, 2015
- Scottish Medicines Consortium (SMC). Product Update: Glatriramer acetate 40mg/mL solution for injection prefilled syringes (Copaxone®). SMC No. (1108/15) Glasgow, Scotland: Scottish Medicines Consortium, 2015. https://www.scottishmedicines.org.uk/files/advice/glatiramer_acetate__Copaxane__Abbreviated_FINAL_Nov_2015_for_website.pdf. Accessed October 3, 2016
- Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol 2011;11:122
- Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19:S24-S40
- Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
- Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
- Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
- Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
- Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13:657-65
- Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522; discussion 522
- Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
- Cooper K, Bryant J, Harris P, et al. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a single technology appraisal. Evidence Review Group Report commissioned by the NIHR HTA Programme on behalf of NICE. The Southampton Health Technology Assessments Centre (SHTAC), 2013. https://www.nice.org.uk/guidance/ta312/documents/multiple-sclerosis-relapsingremitting-alemtuzumab-evaluation-report3. Accessed November 2, 2014
- CRD and CHE Technology Assessment Group. Fingolimod for the treatment of relapsing remitting multiple sclerosis. University of York, Heslington, York: Centre for Reviews and Dissemination/Centre for Health Economics, 2011. http://www.nice.org.uk/guidance/ta254/documents/multiple-sclerosis-relapsingremitting-fingolimod-appraisal-consultation-evidence-review-group-report2. Accessed September 4, 2014
- Peninsula Technology Assessment Group (PenTAG). The effectiveness and cost-effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen. Evidence Review Group Report commissioned by NHS R&D HTA Programme on behalf of NICE. 2007. https://www.nice.org.uk/guidance/ta127/documents/multiple-sclerosis-natalizumab-evaluation-report-evidence-review-group-report2. Accessed Septembber 4, 2014
- Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16:231-50
- Scottish Medicines Consortium (SMC). Guidance to manufacturers for completion of New Product Assessment Form (NPAF). Glasgow, Scotland: Scottish Medicines Consortium, 2016. http://www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission. Accessed October 3, 2016
- HM Treasury. The Green Book: appraisal and evaluation in Central Government. London: HM Treasury, 2003, updated 2011. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/220541/green_book_complete.pdf. Accessed April 30, 2015
- Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
- Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980. Acta Neurol Scand 1982;65:248-66
- Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
- Eurostat. Harmonised Indices of Consumer Prices. HICP (2005 = 100)-monthly data (index). Luxembourg: European Commission, 2016. http://ec.europa.eu/eurostat/web/hicp/data/database. Accessed January 30, 2016
- Hernandez L, Guo S, Kinter E, et al. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. J Med Econ 2016;19:684-95
- Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. Section 1. Clinical course and disability. Brain 1989;112:133-46
- Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. Section 2. Predictive value of the early clinical course. Brain 1989;112:1419-28
- Tolley K, Hutchinson M, You X, et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon Beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One 2015;10:e0127960
- Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16
- Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2012;18:418-24
- Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14
- Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
- Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-7
- Ebers GC, Rice G, Lesaux, J, et al. Randomised double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
- Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113:283-7
- Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
- Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327-40
- Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
- O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97
- Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007;29:2031-48
- Human Mortality Database. National Life Tables 2013, Scotland. Berkeley, CA: University of California; Germany: Max Planck Institute for Demographic Research, 2015. http://www.mortality.org/cgi-bin/hmd/country.php?cntr=GBRTENW&level=1. Accessed April 30, 2015
- Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010;96:5-21
- Tyas D, Kerrigan J, Russell N, et al. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health 2007;10:386-9
- Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Canterbury, UK: Personal Social Services Research Unit, The University of Kent, 2015. http://www.pssru.ac.uk/project-pages/unit-costs/2015/. Accessed February 12, 2016
- National Health Service (NHS). National Schedule of Reference Costs. Year 2014-15 - All NHS trusts and NHS foundation trusts - Outpatient Attendances Data. London: Department of Health, 2015. https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015. Accessed January 30, 2016
- National Health Service (NHS). National Schedule of Reference Costs. Year 2014-15 - NHS trusts and NHS foundation trusts. Direct Access Pathology Services (DAPS): Haematology (DAPS05). London: Department of Health, 2015. https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015. Accessed January 30, 2016
- National Health Service (NHS). National Schedule of Reference Costs. Year 2014-15 - NHS trusts and NHS foundation trusts. Direct Access Pathology Services (DAPS): Clinical Biochemistry (DAPS04). London: Department of Health, 2015. https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015. Accessed January 30, 2016
- National Institute for Health and Clinical Excellence (NICE). Natalizumab Costing Template and Report. Technology Appraisal Guidance TA127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. London: National Institute for Health and Clinical Excellence, 2007. http://www.nice.org.uk/guidance/ta127/costing. Accessed September 4, 2014
- Barendregt JJ. The life table method of half cycle correction: getting it right. Med Decis Making 2014;34:283-5
- Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014;4:e004073
- Inusah S, Sormani MP, Cofield SS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler 2010;16:1414-21
- Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
- Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37
- Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2015;21:1025-35
- Fogarty E, Schmitz S, Tubridy N, et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Mult Scler Relat Disord 2016;9:23-30